Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXLNASDAQ:CRDFNYSE:NUVBNASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$8.17+0.6%$8.91$3.51▼$14.44$697.49M0.821.22 million shs894,021 shsCRDFCardiff Oncology$2.67-1.8%$3.06$2.01▼$5.64$177.62M1.811.12 million shs949,340 shsNUVBNuvation Bio$2.14-2.3%$2.00$1.54▼$3.97$724.77M1.422.21 million shs3.28 million shsVIRVir Biotechnology$4.50-4.3%$6.08$4.35▼$14.45$621.29M1.361.37 million shs2.52 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences+0.62%-3.37%-7.37%-3.54%+89.56%CRDFCardiff Oncology-1.84%+7.23%-4.30%-35.66%-25.42%NUVBNuvation Bio-2.28%+5.42%+5.68%-6.35%-35.25%VIRVir Biotechnology-4.26%-19.79%-19.21%-53.03%-55.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVXLAnavex Life Sciences3.8205 of 5 stars3.71.00.04.72.70.80.6CRDFCardiff Oncology1.4403 of 5 stars3.50.00.00.03.20.00.6NUVBNuvation Bio3.5565 of 5 stars4.60.00.00.02.85.00.6VIRVir Biotechnology2.6944 of 5 stars3.41.00.00.02.43.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 3.33Buy$44.00438.56% UpsideCRDFCardiff Oncology 3.00Buy$12.00349.44% UpsideNUVBNuvation Bio 3.17Buy$7.83266.04% UpsideVIRVir Biotechnology 2.86Moderate Buy$32.86630.16% UpsideCurrent Analyst Ratings BreakdownLatest CRDF, VIR, AVXL, and NUVB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $14.005/9/2025CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.004/23/2025NUVBNuvation BioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/23/2025NUVBNuvation BioCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMkt Outperform$6.004/23/2025NUVBNuvation BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$6.004/17/2025VIRVir BiotechnologyThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $21.004/7/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.004/7/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.003/31/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.003/27/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.003/12/2025NUVBNuvation BioJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/ACRDFCardiff Oncology$587K302.60N/AN/A$1.56 per share1.71NUVBNuvation Bio$7.87M92.06N/AN/A$2.76 per share0.78VIRVir Biotechnology$14.30M43.44N/AN/A$11.82 per share0.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-37.50%-34.08%N/ACRDFCardiff Oncology-$41.44M-$0.92N/AN/AN/A-6,238.17%-73.97%-60.40%N/ANUVBNuvation Bio-$75.80M-$2.35N/AN/AN/AN/A-21.89%-17.86%N/AVIRVir Biotechnology-$615.06M-$4.22N/AN/AN/A-678.40%-36.71%-31.00%7/30/2025 (Estimated)Latest CRDF, VIR, AVXL, and NUVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q2 2025AVXLAnavex Life Sciences-$0.16-$0.13+$0.03-$0.13N/AN/A5/8/2025Q1 2025CRDFCardiff Oncology-$0.19-$0.20-$0.01-$0.20$0.09 million$0.11 million5/7/2025Q1 2025NUVBNuvation Bio-$0.16-$0.16N/A-$0.16$0.42 million$3.08 million5/7/2025Q1 2025VIRVir Biotechnology-$0.83-$0.88-$0.05-$0.88$8.59 million$3.03 million2/26/2025Q4 2024VIRVir Biotechnology-$0.85-$0.76+$0.09-$0.76$8.14 million$12.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A9.459.45CRDFCardiff OncologyN/A4.744.74NUVBNuvation BioN/A9.579.57VIRVir BiotechnologyN/A8.948.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%CRDFCardiff Oncology16.29%NUVBNuvation Bio61.67%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.40%CRDFCardiff Oncology7.70%NUVBNuvation Bio29.93%VIRVir Biotechnology15.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4085.37 million75.71 millionOptionableCRDFCardiff Oncology2066.53 million47.15 millionOptionableNUVBNuvation Bio60338.68 million319.50 millionOptionableVIRVir Biotechnology580138.06 million116.24 millionOptionableCRDF, VIR, AVXL, and NUVB HeadlinesRecent News About These CompaniesVir Biotechnology (NASDAQ:VIR) Given New $14.00 Price Target at Needham & Company LLCMay 14 at 10:07 AM | marketbeat.comVir Biotechnology (NASDAQ:VIR) Price Target Cut to $14.00 by Analysts at Needham & Company LLCMay 13 at 1:56 AM | americanbankingnews.comVir’s hepatitis B combo falls short in Phase II trialMay 12 at 10:46 PM | msn.comVir Biotechnology to Participate in Bank of America Securities 2025 Healthcare ConferenceMay 12 at 4:05 PM | businesswire.comBridgeway Capital Management LLC Sells 66,538 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)May 12 at 4:46 AM | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by Dimensional Fund Advisors LPMay 11, 2025 | marketbeat.comVir Biotechnology First Quarter 2025 Earnings: Revenues DisappointMay 10, 2025 | finance.yahoo.comDAFNA Capital Management LLC Invests $734,000 in Vir Biotechnology, Inc. (NASDAQ:VIR)May 10, 2025 | marketbeat.comWhy Vir Biotechnology, Inc.’s (VIR) Stock Is Down 5.45%May 10, 2025 | aaii.comQ1 2025 Vir Biotechnology Inc Earnings CallMay 10, 2025 | finance.yahoo.comVir's 'functional cure' candidate for hepatitis B misses mark in phase 2May 10, 2025 | fiercebiotech.comVir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH StudyMay 9, 2025 | businesswire.comVir Biotechnology’s Earnings Call: Mixed Sentiment Amid ProgressMay 8, 2025 | tipranks.comVir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV TreatmentMay 8, 2025 | seekingalpha.comVir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virusMay 8, 2025 | msn.comVir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...May 8, 2025 | uk.finance.yahoo.comVir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comVir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue EstimatesMay 7, 2025 | zacks.comVir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 7, 2025 | businesswire.com1,084,539 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Bought by Baker BROS. Advisors LPMay 6, 2025 | marketbeat.comWells Fargo & Company MN Has $387,000 Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)May 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to BenefitCrowdStrike Stock Is a Buy as Cyberthreat Environment ExpandsBy Chris Markoch | April 15, 2025View CrowdStrike Stock Is a Buy as Cyberthreat Environment ExpandsMedtronic: A Dividend Aristocrat With Stability and InnovationBy Jeffrey Neal Johnson | April 22, 2025View Medtronic: A Dividend Aristocrat With Stability and InnovationCRDF, VIR, AVXL, and NUVB Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$8.17 +0.05 (+0.62%) As of 05/14/2025 04:00 PM EasternAnavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Cardiff Oncology NASDAQ:CRDF$2.67 -0.05 (-1.84%) As of 05/14/2025 04:00 PM EasternCardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Nuvation Bio NYSE:NUVB$2.14 -0.05 (-2.28%) As of 05/14/2025 03:48 PM EasternNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Vir Biotechnology NASDAQ:VIR$4.50 -0.20 (-4.26%) As of 05/14/2025 04:00 PM EasternVir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
